Dr. Lu-Lu Yang is the recepient of the IASLC / Boehringer Ingelheim Chinese Research Fellowship Award. The goal of this fellowship is to reward scientific excellence and to encourage innovative investigations in the field of lung cancer prevention and translational research with a potential impact on the management of lung cancer.
Dr. Yang comes from the Guangdong Lung Cancer Institute studing under Dr. Yi-Long Wu. Her fellowship research, under the guidance of Dr. Pase Janne at the Dana-Farber Cancer Institute, will examine the effects of combination treatment with selumetinib, a MEK 1/2 inhibitor, and pemetrexed, an anti-folate drug, in KRAS mutant non-small cell lung cancer and the mechanisms of acquired resistance.
Dr. Yang has had a long-standing interest in lung cancer research and plans to persue a career in lung cancer control and translational research. She hopes to make signficiant achievments through this fellowship and states "This IASLC award will improve my scientific research capacity and mode of thinking for my career".